Abstract Number: 1598 • 2012 ACR/ARHP Annual Meeting
Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – the RIM Study
Background/Purpose: The Rituximab in Myositis (RIM) Study evaluated 200 refractory myositis patients treated with rituximab, 83% of whom met the definition of improvement (DOI). The…